Research programme - microbiome therapeutics - Seres Therapeutics/Memorial Sloan Kettering Cancer Center

Drug Profile

Research programme - microbiome therapeutics - Seres Therapeutics/Memorial Sloan Kettering Cancer Center

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Seres Therapeutics
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Graft-versus-host disease

Most Recent Events

  • 12 May 2016 Preclinical research in Cancer in USA (unspecified route)
  • 12 May 2016 Preclinical research in Graft-versus-host disease (Prevention) in USA (unspecified route)
  • 12 May 2016 Microbiome therapeuticsTM platform licensed to Seres therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top